Being used by more than 200 health systems TODAY, Eko Telehealth incorporates stethoscope and ECG live-streaming combined with embedded video conferencing and FDA-cleared AI algorithms for heart murmur and AFib detection.
Eko Telehealth offers AI-powered and FDA-cleared identification of heart murmurs and atrial fibrillation, assisting providers in the detection and monitoring of heart disease during virtual visits; lung and heart sound live-streaming for a thorough virtual examination; single-lead ECG live-streaming, enabling providers to assess for rhythm abnormalities; and embedded HIPAA-compliant video conferencing, or can work alongside the video conferencing platform a health system has in place.
Symptoms of valvular heart disease and AFib often go undiagnosed during routine physical exams.
With the development of Eko's AI screening algorithms, clinicians are able to harness machine learning to detect heart disease at the earliest point of care regardless if the patient visit is in-person or remote.
With Eko, a provider at a patient site, such as a hospital, rural clinic or nursing home can stream stethoscope audio and ECG to a physician residing in a separate room or at a virtual care center, medical center or specialty clinic, thus reducing in-person exposure to infectious diseases, like COVID-19.
The Eko DUO is the first combined digital stethoscope and 1-lead ECG device designed specifically for patients to operate at home, under the supervision of a healthcare provider.
For COVID-19 cases being monitored remotely, Eko helps providers assess worsening symptoms while reducing the need for patients to travel to a medical site and risk exposure or continued spread of COVID-19.
Eko is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis.
Its FDA cleared platform is used by tens of thousands of clinicians treating ms of patients around the world, in-person, and through telehealth.
The company is headquartered in Oakland, California and privately-held, with investments from ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, Sutter Health and others.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial